Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
sEwEuMk9zkhnXcE9
